Proteins and Peptides

03 May 2018 Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
02 May 2018 Bioniz Therapeutics Announces Positive Phase 1b Clinical Study Results for Investigational Agent BNZ-1
30 Apr 2018 Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
30 Apr 2018 Medtronic Announces FDA Approval of Infuse(TM) Bone Graft in New Spine Surgery Indications Using PEEK Interbody Implants
25 Apr 2018 Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer's Disease
24 Apr 2018 New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors
19 Apr 2018 Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo
19 Apr 2018 AzurRx BioPharma Announces Positive Preclinical Data with AZX1103
18 Apr 2018 Merck Presents New Osteoarthritis Data at OARSI 2018 World Congress
17 Apr 2018 FDA approves Vonvendi [von Willebrand factor (recombinant)] for perioperative management of bleeding in adult patients with von Willebrand disease1
16 Apr 2018 Apitope announces positive results with novel treatment for Graves’ disease
15 Apr 2018 NGM Bio Announces Results From Phase 2 Study Of NGM282 In NASH Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks
12 Apr 2018 Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
11 Apr 2018 Molecular Partners and AstraZeneca announce collaboration on Molecular Partners’ ongoing oncology clinical study with MP0250 in EGFR-mutated NSCLC
11 Apr 2018 Kineret® (anakinra) approved in the EU for the treatment of Still’s diseas
07 Apr 2018 Chiesi Group receives the European Marketing Authorisation for Lamzede (velmanase alfa)
05 Apr 2018 Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401
05 Apr 2018 Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint
03 Apr 2018 US FDA Approves BYDUREON for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
03 Apr 2018 Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases
02 Apr 2018 Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
02 Apr 2018 Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis
02 Apr 2018 Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
30 Mar 2018 Rights to botulinum toxin type b Neurobloc® in Europe transferred to Sloan Pharma, s.à.r.l.
29 Mar 2018 High Point Clinical Trials Center and Amyndas Pharmaceuticals Announce the Completion of the Complement C3 Inhibitor AMY-101 First in Human Study

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up